Anti Coag, Antithrombolitic, Diuretic Tables PDF

Anti Platelets +-----------+-----------+-----------+-----------+-----------+-----------+ | **Medicat | **MOA** | **Indicat | **Contrai | **Side | **Other** | | ion** | | ions** | ndication | Effects** | | | | | | s** | |...

Anti Platelets +-----------+-----------+-----------+-----------+-----------+-----------+ | **Medicat | **MOA** | **Indicat | **Contrai | **Side | **Other** | | ion** | | ions** | ndication | Effects** | | | | | | s** | | | +===========+===========+===========+===========+===========+===========+ | **Aspirin | Inhibits | Acute | ASA or | Bleeding | PO and PR | | ** | cyclooxyg | coronary | NSAID-ind | | | | | enase, | syndrome | uced | Abdominal | | | **"ASA"** | reduces | (ACS) | asthma | Bleed/ulc | | | | platelet | | | er | | | | aggregati | MI | GI | | | | | on | prophylax | bleeding | Bronchosp | | | | | is | | asm | | | | | | Hepatic | | | | | | TIA/throm | Impairmen | | | | | | boembolic | t | | | | | | stroke | and Renal | | | | | | preventio | Failure | | | | | | n | | | | +-----------+-----------+-----------+-----------+-----------+-----------+ | **Glycopr | Reversibl | Acute | Active | Bleeding | IV | | otein | y | Coronary | Bleeding | | administr | | IIb/IIIa | inhibits | Syndrome | | Thrombocy | ation | | inhibitor | the | (ACS) | | topenia | | | s** | binding | | | | Rarely | | | of GP | High risk | | | used due | | **(abcixi | IIb/IIIa | pt's with | | | to | | mab, | receptors | dual | | | availabil | | eptifibat | to | antiplate | | | ity | | ide, | fibrinoge | let | | | of DAPT | | tirofiban | n | therapy | | | and PY12 | | )** | and von | (DAPT) | | | meds | | | Willebran | failure | | | | | | d | | | | | | | factor | Urgent | | | | | | -\> | cardiac | | | | | | impairing | surgery | | | | | | formation | after | | | | | | of | cardiac | | | | | | hemostati | catheteri | | | | | | c | zation | | | | | | plug | | | | | +-----------+-----------+-----------+-----------+-----------+-----------+ | **P2Y12 | Binds to | Acute | Active | Active | Oral | | Inhibitor | P2Y12 | Coronary | bleeding | bleeding | medicatio | | s** | adenosine | Syndrome | | or | n | | | diphospha | (ACS) | | intracran | | | **(clopid | te | | | ial | | | ogrel, | receptors | CAD | | hemorrhag | | | prasugrel | , | | | e | | | , | reducing | Preventio | | | | | ticagrelo | platelet | n | | Dyspnea | | | r)** | activatio | of | | | | | | n | thromboem | | | | | | and | bolic | | | | | | aggregati | event | | | | | | on | | | | | | | | Acute | | | | | | | ischemic | | | | | | | stroke | | | | | | | | | | | | | | TIA | | | | +-----------+-----------+-----------+-----------+-----------+-----------+ Anti Coagulants \*Indirect Thrombin Inhibitors +-----------+-----------+-----------+-----------+-----------+-----------+ | **Medicat | **MOA** | **Indicat | **Contrai | **Side | **Other** | | ion** | | ions** | ndication | Effects** | | | | | | s** | | | +===========+===========+===========+===========+===========+===========+ | **\*Hepar | Activates | Preventio | Active | Bleeding | IV or SQ | | inIV | | lycerin,* | the | Heart | Severe | ia | | | * | plasma | Failure | anemia | | [Short | | | membrane | | | HA | acting]{. | | **Isosorb | of the | Acute | Increased | | underline | | ide | cell | Ischemic | intracran | Flushing | }: | | mononitra | vascular | syndromes | ial | | 15-30 | | te)** | smooth | | pressure | | min, can | | | muscle | | | | be used | | | relaxatio | | | | acutely | | | n | | | | or | | | | | | | prophylac | | | | | | | tically | | | | | | | (i.e. | | | | | | | before | | | | | | | exercise) | | | | | | | | | | | | | | *Long | | | | | | | Acting*: | | | | | | | prevent | | | | | | | chest | | | | | | | discomfor | | | | | | | t | | | | | | | in | | | | | | | chronic | | | | | | | CAD, can | | | | | | | develop | | | | | | | drug | | | | | | | tolerance | +-----------+-----------+-----------+-----------+-----------+-----------+ | **Beta | Decrease | **Ischemi | Caution | Exacerbat | PO | | Blockers | inotropic | c | with | e | | | /** | effects | Heart | diabetics | **broncho | \*Selecti | | | slow | Disease** | / | spasm** | ve | | **Beta-Ad | heart | | insulin | | (β1) or | | renergic | rate and | **Heart | therapy | **Bradyca | nonselect | | Antagonis | decreased | Failure** | (can mask | rdia** | ive | | ts** | oxygen | | hypoglyce | | (β1+ β2) | | | demand | **Hyperte | mia) | **Fatigue | can | | **(Carved | | nsion** | | ** | affect | | ilol** | Decrease | | Caution | | side | | | renin and | | with | Arterial | effects/t | | **Propran | cardiac | | CCB's | vasospasm | arget | | olol** | output | | | | of | | | | | Asthma/ | | medicatio | | **Atenolo | | | COPD | | n | | l** | | | | | | | | | | | | | | **Nadolol | | | | | | | )** | | | | | | +-----------+-----------+-----------+-----------+-----------+-----------+